RI Pharma Alexion Closing Plant and Cutting 250 Jobs
Wednesday, September 13, 2017
Rhode Island will realize job loss of 250 with Alexion's departure and the news hits just days after Benny’s announced the company’s closing and the loss of over 700 full and part-time jobs in the region.
"We are disappointed by today's news regarding Alexion’s restructuring moves. Our number one priority is ensuring that every Rhode Islander currently employed at Alexion is able to transition to other work. The Department of Labor and Training will be working with Alexion officials on re-employment of their employees and the Commerce Corporation will be working with them on repurposing the facility,” said RI Commerce in a statement on Tuesday morning.
The winner in the Alexion slashing is Boston, of course. The company announced that in addition to closing the RI facility and slashing jobs, it is moving its headquarters from New Haven, CT to Boston.
“By streamlining our operations we will create a leaner organization with greater financial flexibility that is highly focused on delivering for patients, growing our rare disease business, and both leveraging our leadership in complement and pursuing disciplined business development to expand the pipeline,” said Ludwig Hantson, Chief Executive Officer of Alexion in a statement. "These types of changes are difficult and we recognize that they have a personal impact on people who have been dedicated to the mission of Alexion. We thank our employees for their contributions to the achievements of Alexion. While difficult, these changes were necessary to enable the Company to deliver sustainable long-term performance to support our ability to continue to develop and deliver life-changing therapies for patients.”
Two Time Loser
Alexion's facility was funded by Rhode Island taxpayers in the early 1990s.
“In 1992, Rhode Island succeeded in enticing Alpha-Beta to build its manufacturing plant outside of Massachusetts. Rhode Island borrowed $30 million to construct the 40,000-square-foot manufacturing facility in Smithfield. In addition, Rhode Island spent about $3 million to buy a 120-acre parcel where the plant was built,” wrote Boston Business Journal in 1999.
- NEW: RI to Receive $75k from Pharmaceutical Settlement
- Pharmaceutical Fraud Settlement Recovers More Than $170K for RI Medicaid
- URI College of Pharmacy Gets NIH Grant, Expands
- Orientation for CCRI’s Comprehensive Pharmacy Tech Program
- NEW: RI Receives $2.6M in Settlement with Janssen Pharmaceuticals
- NEW: Smithfield Pharmacy Suspended For Prescription Violations
- PODCAST: Pharmaceutical Companies Pay RI Doctors Big Money
- Cashing In: RI Doctors Paid Millions By Pharmaceutical Companies
- NEW: Warwick Pharmacist Suspended For Unclean Practices
- NEW: RI Pharmacist Leo Blais Suspended For Dangerous & Lax Practices
- NEW: Kilmartin Urges More Pharmacies to Stop Selling Tobacco in RI
- Lifespan Pharmacy Earns URAC Accreditation
- Stolen Valor, Sex Trafficking, and Tobacco at Pharmacies: This Week at the State House
- CVS Health and Target Sign $1.9 Billion Deal, CVS Acquires Target’s Pharmacies
- New Numbers Break Down Pharmaceutical vs. Illicit Drug ODs in RI
- NEW: URI Pharmacy Professor Awarded $1.3M Grant to Fight Cancer
- BREAKING: RI Health Dir. Fine Halts Suspension of Pharmacist Blais
- URI Pharmacy Professor Awarded $1.65 Mil Grant To Study Alcoholism
- CVS Pharmacies Set to Open in Target Stores Across The Country